فارما جو – عمان اشغلت الرسالة الخلوية التي وزعت على الصيادلة وتتحدث عن خسائر في صندوق التقاعد تصل الى ستة ملا [ ... ]
تسجيل الدخول/حساب جديد
الخميس, 24 أيار 2012 3. رجب 1433
|
|
|
|
|
|
 |
فارما جو – د. احمد ابوغنيمة قد يبدو للمتابع لنتائج انتخابات نقابة الصيادلة التي جرت يوم الجمعة الموافق 18/5/20012 [ ... ]
متى سيتم صرف الادوية بهذه الطريقة ؟؟؟ وهل تعتقدون ان هذه الطريقة ستنجح لدينا في الدول العربية ؟؟؟ ثم ما هو مصير الصيدلاني ؟؟؟…
فارما جو – عمان التقى عطوفة رئيس المجلس القضائي الأعلى القاضي محمد المحاميد مدير عام المؤسسة العامة [ ... ]
- ضبط ادوية مهربة ومستحضرات مخدرة وقطرات ( مثيرة جنسيا للفتيات) لدى طبيب في منطقة الوحدات
- ممثلين عن (الفاو) يبحثون مع مدير عام JFDA د. عبيدات مجالات التعاون بين المؤسسة ومنظمة الاغذية والزراعة الدوليه
- فارما جو تلتقي د. الحمود مديرة الدواء في JFDA في حديث هام وموسع
- تعيين الدكتور هايل عبيدات مديرا عاما للمؤسسسة العامة للغذاء والدواء خلفا للدكتور الروابده وفارما جو تهنئ
- جهل العطارين والأطباء الشعبيين بالمجاميع الكيميائية في الاعشاب يجعل خلطاتهم العشبية العشوائية خطراً على [ ... ]
FDA Approves Benlysta
نشر بتاريخ السبت, 12 آذار/مارس 2011 15:13 | | 
| 
| الزيارات: 365
| | الزيارات: 365
The U.S. Food and Drug Administration has approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs.
Benlysta is delivered directly into a vein (intravenous infusion) and is the first inhibitor designed to target B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells thought to be a problem in lupus.
Prior to Benlysta, FDA last approved drugs to treat lupus, Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. Aspirin was approved to treat lupus in 1948.
Benlysta Medication Guide
Read this Medication Guide before you start receiving Benlysta and before each treatment. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
Benlysta is delivered directly into a vein (intravenous infusion) and is the first inhibitor designed to target B-lymphocyte stimulator (BLyS) protein, which may reduce the number of abnormal B cells thought to be a problem in lupus.
Prior to Benlysta, FDA last approved drugs to treat lupus, Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. Aspirin was approved to treat lupus in 1948.
Benlysta Medication Guide
Read this Medication Guide before you start receiving Benlysta and before each treatment. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
Important information about Benlysta
Benlysta can cause serious side effects. ome of these side effects may cause death. It is not known if Benlysta causes these serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while receiving Benlysta.
1. Infections. Symptoms of an infection can include:
* fever
* chills
* pain or burning with urination
* urinating often
* bloody diarrhea
* coughing up mucus
2. Heart Problems. Symptoms of heart problems can include:
* chest discomfort or pain
* shortness of breath
* cold sweats
* nausea
* dizziness
* discomfort in other areas of the upper body
3. Mental health problems and suicide. Symptoms of mental health problems can include:
* thoughts of suicide or dying
* attempt to commit suicide
* trouble sleeping (insomnia)
* new or worse anxiety
* new or worse depression
* acting on dangerous impulses
* other unusual changes in your behavior or mood
* thoughts of hurting yourself or others
